Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study
ConclusionsAdavosertib 175 mg bid for 2.5 days was chosen as the recommended Phase II dose in combination with paclitaxel and carboplatin in Asian patients.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer & Oncology | Chemotherapy | Respiratory Medicine | Study | Thrombocytopenia | Toxicology